Company: GNMSF
Filing Date: 2025-08-07
Form Type: 6-K
Source: 0001434265-25-000063
Chunk: 54

Company: GENMAB A/S
Filing Date: 2025-08-07
Form: 6-K
Chunk 54
---
INLY ® , TEPKINLY ® and their designs are trademarks of AbbVie Biotechnology Ltd.; Kesimpta ® and Sensoready ® are trademarks of Novartis AG or its affiliates; DARZALEX ® , DARZALEX FASPRO ® , RYBREVANT ® , TECVAYLI ® and TALVEY ® are trademarks of Johnson & Johnson; TEPEZZA ® is a trademark of Horizon Therapeutics Ireland DAC.

| Genmab A/S            
 Carl Jacobsens Vej 30 
 2500 Valby, Denmark   |     | Tel: +45 7020 2728 
 www.genmab.com     |     | Company Announcement no. 40 
 Page 43/44                  
 CVR no. 2102 3884           |

#### Interim Report for the First Half of 2025
DIRECTORS’ AND MANAGEMENT’S STATEMENT ON THE INTERIM REPORT

The Board of Directors and the registered members of Executive Management have today considered and adopted the unaudited interim report of the Genmab Group for the six months ended June 30, 2025.

The interim report is prepared in accordance with IAS 34, “Interim Financial Reporting,” as issued by the IASB and in accordance with IAS 34 as endorsed by the EU, and additional Danish disclosure requirements for interim reports of listed companies.

We consider the applied accounting policies to be appropriate and, in our opinion, the interim report gives a true and fair view of the assets and liabilities, financial position, results of operation and cash flows of the Group.

Furthermore, we consider the Management’s Review to give a true and fair account of the development in the Group’s activities and financial affairs, results of operations and the Group’s financial position as a whole as well as a description of the significant risks and uncertainties which the Group faces, as further described in this report, our 2024 Annual Report and the Form 20-F filed with the U.S. Securities and Exchange Commission in February 2025.

Copenhagen, 7 August 2025

#### Registered Members of Executive Management
| Jan van de Winkel 
 (President & CEO) |     | Anthony Pagano                   
 (Executive Vice President & CFO) |

#### Board of Directors
| Deirdre P. Connelly 
 (Chair)             |     | Pernille Erenbjerg 
 (Deputy Chair)     |     | Anders Gersel Pedersen |
|